On the morning of December 23, Aba Chemicals Corporation(300261) raised the 20cm limit again. The company's share price rose more than 70% in the last four trading days.
On the news, the company announced on the evening of the 22nd that it did not directly supply carlon anhydride products to Pfizer and had no direct cooperation relationship with Pfizer. In addition, the sales revenue of carbonic anhydride products accounts for a relatively small proportion, which will not have a significant impact on the company's performance.
share price continued to rise
On the morning of December 23, Aba Chemicals Corporation(300261) opened high and rose rapidly. As of midday closing, Aba Chemicals Corporation(300261) was reported at 12.88 yuan / share, an increase of 20.04%, with a turnover of 483 million yuan.
According to the data of China Securities Taurus, Aba Chemicals Corporation(300261) continued to rise sharply. Two 20cm trading limits were harvested in the four trading days, with a cumulative increase of about 75%.
According to the dragon and tiger list data on the 22nd, the top five business departments with the largest purchase amount bought 206 million yuan in total, and the top five business departments with the largest sales amount sold 107 million yuan in total, with a net purchase amount of 98.6507 million yuan.
On the news, on December 22, US Eastern time, Pfizer announced that the emergency authorization application for covid-19 oral drug paxlovid was approved by the US Food and Drug Administration (FDA), which is the first oral antiviral drug authorized by FDA to treat covid-19 diseases.
Previously, Pfizer announced the latest data of covid-19 oral drug paxlovid in the treatment of mild covid-19 phase 2 / 3. The effective rate of reducing hospitalization rate or mortality was still 89%, and the in vitro test confirmed that it was still effective for Omicron mutant.
Insiders said that the core component of the drug is pf-07321332. China International Capital Corporation Limited(601995) in the Research Report at the beginning of December, it focused on the intermediate carbonic anhydride for synthesizing PF. Previously, media reported that the pharmaceutical intermediate carbonic anhydride developed and produced by Aba Chemicals Corporation(300261) has been commercialized and mass produced.
no direct cooperation with Pfizer
On the evening of December 22, Aba Chemicals Corporation(300261) issued an announcement on abnormal fluctuations in stock trading, saying that there had been no significant changes in the company's recent operation and internal and external business environment. Up to now, the company has not directly signed any cooperation agreement with Pfizer, has no direct cooperation relationship with Pfizer, and has not directly supplied carlon anhydride products to Pfizer. Source: company announcement
The announcement also said that the sales revenue of the company's carbonic anhydride products accounts for a small proportion of the company's annual total operating revenue and will not have a significant impact on the company's performance.
For investors' questions about the use of carbonic anhydride, Aba Chemicals Corporation(300261) replied on the interactive platform on December 7 that carbonic anhydride was originally a bosepivir intermediate developed and produced by the company in the early stage, and applied for relevant patents. At present, the sales revenue of the product accounts for a small proportion of the company's annual total operating revenue, which will not have a significant impact on the company's performance.
actively expand pharmaceutical intermediates and big health business
According to the data, Aba Chemicals Corporation(300261) main business is divided into three sectors: pesticide intermediates, pharmaceutical intermediates and big health products. According to the operating revenue, the sales revenue of pesticide intermediates accounts for about 70% of the company's total revenue, and the sales revenue of pharmaceutical intermediates and big health products accounts for about 30% of the total revenue.
Among them, for the development plan of pharmaceutical intermediates and big health industry to be strengthened in the future, previously Aba Chemicals Corporation(300261) said that the company is investing in the construction of Shangyu base in Shangyu, Zhejiang Province, and will enable the company's pharmaceutical intermediates and big health business through rolling development, and launch large-scale, high technical barriers and high value-added commercial pharmaceutical products, Expand the production of existing pharmaceutical products and extend to the downstream API, cultivate and enlarge the pharmaceutical products in the pipeline, and consolidate the foundation for the development of pharmaceutical business.
The company will also further enrich big health products, make use of the advantages and accumulation of the company's synthetic biotechnology platform, and constantly launch new products with green, safety, environmental protection and high quality.
(China Securities Journal)
